70
Registered trials
30
Recruiting
35
Completed trials
43
Sponsors
25
Countries
Phase III:
21
Phase II/III:
1
Phase II:
38
Phase I/II:
3
Phase III/IV:
1
Phase IV:
3
Phase I (Other):
1
Phase I (FiH):
2
Oversight events:
3 serious breaches
15 temporary halts
2 urgent safety measures
1 unexpected event
across 7 trials
View oversight register →
Indications tested
Ovarian cancer
7
Triple negative breast cancer
5
Fallopian tube cancer
4
Ovarian cancer recurrent
4
Breast cancer
3
Breast cancer metastatic
3
Ovarian epithelial cancer
2
Endometrial cancer
2
Breast cancer female
2
Fallopian tube cancer metastatic
1
Non-small cell lung cancer
1
Prostate cancer metastatic
1
Sponsors using this IMP
Merck Sharp & Dohme LLC
12
AstraZeneca AB
11
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
3
IRCCS Istituto Nazionale Tumori Fondazione Pascale
3
AGO Research GmbH
2
Institut Gustave Roussy
2
Region Hovedstaden
2
Artios Pharma Limited
1
Asociacion Grupo Tratamiento De Tumores Digestivos
1
Astrazeneca Farmaceutica Spain S.A.
1
Azienda Ospedaliero Universitaria Di Modena
1
Belgian Society Of Medical Oncology
1
All trials — page 3
70 totalShowing 49–70 of 70 trials